Novel treatment options for secondary hyperparathyroidism in end-stage kidney disease patients on hemodialysis therapy | Zendy

Liudmila Rozhinskaya | Zendy; Zhanna Belaya | Zendy; Alexander Lutsenko | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Novel treatment options for secondary hyperparathyroidism in end-stage kidney disease patients on hemodialysis therapy

Author(s) -

Liudmila Rozhinskaya,

Zhanna Belaya,

Alexander Lutsenko

Publication year - 2017

Publication title -

osteoporosis and bone diseases

Language(s) - English

Resource type - Journals

eISSN - 2311-0716

pISSN - 2072-2680

DOI - 10.14341/osteo2017126-33

Subject(s) - cinacalcet , secondary hyperparathyroidism , medicine , calcimimetic , dialysis , hemodialysis , parathyroid hormone , hyperparathyroidism , urology , end stage renal disease , kidney disease , agonist , endocrinology , calcium , receptor

Pathogenesis of secondary hyperparathyroidism is based on D-hormone deprivation, leading to bone remodeling impairment, increase in FGF-23, PTH levels, changes in blood calcium and phosphorus levels. Taken together with alteration of calcium-sensing receptor (CaSR) sensitivity, these changes result in alteration of bone structure and cardiovascular complications. CaSR agonists are one of the most important medications for treatment of secondary hyperparathyroidism in dialysis patients. Until recently, there was only one CaSR agonist with proven effectiveness – cinacalcet, which is administered per os , daily. Now, a new drug is registered in US, Europe and Russia – etelcalcetide, which is administered intravenously 3 times a week. In this review we focus on results of clinical trials regarding etelcalcetide effectiveness and possible compliance benefits.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research